MS Learn Online presents two webcasts on Gilenya, the first oral disease-modifier approved for the treatment of MS. Join host Aaron Miller, MD, chief medical officer for the National MS Society, as he discusses the clinical trial findings on Gilenya, how the drug works and who should consider taking it. Transcripts of this two-part program are also available in PDF and MP3 podcast formats.
In a recent U.S. study, researchers found that MS disease activity measured by MRI scans in 44 people with MS increased two to three times during the months of March to August compared with other times of the year. What
is the influence of the environment on MS?
Thanks to a generous gift from Mr. Richard Slifka, a longtime donor and leadership volunteer, your donation will be instantly doubled for a limited time only! Donate now and DOUBLE your gift toward a world free of MS.